Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole L Moore

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Oncology|August 29, 2022
The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilitiesJosephine A Hinneh, Joanna L Gillis, Nicole L Moore, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 3, 2008
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptorsElisa J Cops, Tina Bianco-Miotto, Nicole L Moore, et al.
The Biochemical Journal|January 19, 2006
Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alphaHarish Srinivas, Dianren Xia, Nicole L Moore, et al.
Endocrinology|March 14, 2009
A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatinEleanor F Need, Howard I Scher, Amelia A Peters, et al.
Human Molecular Genetics|June 17, 2004
Structural and functional consequences of glutamine tract variation in the androgen receptorGrant Buchanan, Miao Yang, Albert Cheong, et al.
Endocrine-Related Cancer|June 22, 2012
An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activityNicole L Moore, Grant Buchanan, Jonathan M Harris, et al.
Menopause (New York, N.Y.)|May 30, 2013
Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivoAleksandra M Ochnik, Nicole L Moore, Tanja Jankovic-Karasoulos, et al.
Cancer Research|September 17, 2005
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetateGrant Buchanan, Stephen N Birrell, Amelia A Peters, et al.
Cancer Research|July 30, 2009
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancerAmelia A Peters, Grant Buchanan, Carmela Ricciardelli, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Oncology|August 29, 2022
The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilitiesJosephine A Hinneh, Joanna L Gillis, Nicole L Moore, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 3, 2008
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptorsElisa J Cops, Tina Bianco-Miotto, Nicole L Moore, et al.
The Biochemical Journal|January 19, 2006
Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alphaHarish Srinivas, Dianren Xia, Nicole L Moore, et al.
Endocrinology|March 14, 2009
A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatinEleanor F Need, Howard I Scher, Amelia A Peters, et al.
Human Molecular Genetics|June 17, 2004
Structural and functional consequences of glutamine tract variation in the androgen receptorGrant Buchanan, Miao Yang, Albert Cheong, et al.
Endocrine-Related Cancer|June 22, 2012
An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activityNicole L Moore, Grant Buchanan, Jonathan M Harris, et al.
Menopause (New York, N.Y.)|May 30, 2013
Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivoAleksandra M Ochnik, Nicole L Moore, Tanja Jankovic-Karasoulos, et al.
Cancer Research|September 17, 2005
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetateGrant Buchanan, Stephen N Birrell, Amelia A Peters, et al.
Cancer Research|July 30, 2009
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancerAmelia A Peters, Grant Buchanan, Carmela Ricciardelli, et al.
Pageof 2